GPPC Calls for Improved Oversight of PGx Dxs After Uncovering Inconsistent Marketing

Apr 09, 2008

Premium

This article has been updated from a previous version to include comments from Seryx.

Researchers from Johns Hopkins University's Genetics and Public Policy Center last week said they uncovered inconsistencies and misleading claims made by companies selling CYP450 testing services designed to help guide treatments of certain antidepressants.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Yep, Couple of Concerns There

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

Passing on Trauma, Maybe

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.